Captrust Financial Advisors Atara Biotherapeutics, Inc. Transaction History

Captrust Financial Advisors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.23 - $1.74 $14,963 - $113,202	65,059 Added 361.14%	83,074 $42,000
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.31 $25,401 - $41,614	18,015 New	18,015 $26,000
Q1 2023 May 15, 2023	BUY	$2.8 - $5.46 $28,856 - $56,270	10,306 New	10,306 $29,000
Q2 2022 Aug 16, 2022	SELL	$4.69 - $9.84 $37 - $78	-8 Reduced 3.76%	205 $2,000
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $447 - $895	-53 Reduced 19.92%	213 $2,000

Q3 2021 Nov 16, 2021	BUY	$11.99 - $17.9 $119 - $179	10 Added 3.91%	266 $5,000
Q2 2021 Aug 16, 2021	SELL	$12.89 - $16.58 $128 - $165	-10 Reduced 3.76%	256 $4,000
Q1 2021 May 17, 2021	BUY	$14.0 - $20.72 $3,724 - $5,511	266 New	266 $4,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.